BACKGROUND: Patients with hypopharyngeal cancer have a 5-year survival of only 15% to 30%. Human papillomavirus (HPV) is a risk factor and a favorable prognostic factor for oropharyngeal carcinoma and p16 has been suggested as a surrogate marker for HPV-induced cancer. However, few studies have been performed on HPV and p16 in hypopharyngeal cancer. METHODS: One hundred nine pretreatment hypopharyngeal cancer biopsies were analyzed for presence of HPV and p16 overexpression, and the results were correlated to patient survival. RESULTS: Of 109 tumors, 7 were HPV-positive (4 HPV16) and 18 overexpressed p16. There was some correlation between survival and HPV status, but not with regard to p16 expression. Notably, all patients with HPV16-positive tumors, also overexpressing p16, lived tumor free for more than 3 years. CONCLUSION: Our results indicate that HPV-induced hypopharyngeal cancer is rare and that p16 is not a suitable biomarker for presence of HPV in this tumor type.
BACKGROUND:Patients with hypopharyngeal cancer have a 5-year survival of only 15% to 30%. Human papillomavirus (HPV) is a risk factor and a favorable prognostic factor for oropharyngeal carcinoma and p16 has been suggested as a surrogate marker for HPV-induced cancer. However, few studies have been performed on HPV and p16 in hypopharyngeal cancer. METHODS: One hundred nine pretreatment hypopharyngeal cancer biopsies were analyzed for presence of HPV and p16 overexpression, and the results were correlated to patient survival. RESULTS: Of 109 tumors, 7 were HPV-positive (4 HPV16) and 18 overexpressed p16. There was some correlation between survival and HPV status, but not with regard to p16 expression. Notably, all patients with HPV16-positive tumors, also overexpressing p16, lived tumor free for more than 3 years. CONCLUSION: Our results indicate that HPV-induced hypopharyngeal cancer is rare and that p16 is not a suitable biomarker for presence of HPV in this tumor type.
Authors: Lars Sivars; Cinzia Bersani; Nathalie Grün; Torbjörn Ramqvist; Eva Munck-Wikland; Christian Von Buchwald; Tina Dalianis Journal: Mol Clin Oncol Date: 2016-10-13
Authors: Julie Steinestel; Andreas Al Ghazal; Annette Arndt; Thomas J Schnoeller; Andres J Schrader; Peter Moeller; Konrad Steinestel Journal: BMC Cancer Date: 2015-04-03 Impact factor: 4.430
Authors: Lorena Baboci; Dana Holzinger; Paolo Boscolo-Rizzo; Giancarlo Tirelli; Roberto Spinato; Valentina Lupato; Roberto Fuson; Markus Schmitt; Angelika Michel; Gordana Halec; Maria Cristina Da Mosto; Michael Pawlita; Annarosa Del Mistro Journal: Papillomavirus Res Date: 2016-07-16